Specifically, a TREM2-targeting monoclonal antibody (AL002) is currently being assessed in patients with AD (NCT05744401)39, while an inflammasome inhibitor (RO7486967) is under investigation in individuals with PD (NCT05924243). Here, TREM2 is linked to Parkinson disease.